LIVE TICKER
[Live wire]Connecting to the newsroom…
← Back to the news wire
Flesch Reading Ease: 28•350 words from the publisher
AIPublished by TechCrunch AI • 11/17/2026, 2:26:46 PMOpen Original Report (TechCrunch AI) ↗

Science Corporation’s brain tech is worth $3.5 billion after new funding

Science Corporation , the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post .

Science Corporation’s brain tech is worth $3.5 billion after new funding
Image supplied by TechCrunch AI.

Reported by TechCrunch AI

Science Corporation , the medical technology start-up founded by former Neuralink president Max Hodak in 2021, raised a $400 million Series D, the company said in a blog post .

Investors in the new round valued the company at $3.5 billion, a person familiar with the deal told TechCrunch. Those backers included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Hodak, who talked his way into a graduate neuroscience lab as a college student and has pursued biotechnology ever since, co-founded Science to leverage new technologies to understand and interact with the brain.

More from the original report

Science’s first product is PRIMA, a wearable and implantable chip that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, as well as being trialled for new conditions.

Hodak announced that the device is now being trialled for patients with another blindness-causing condition, Stargardt’s disease, while onstage at TechCrunch Disrupt.

With the funding, the company aims to bring the device to the United States through the FDA’s Humanitarian Device Exemption, which lets experimental medical technology be used to treat rare conditions. Science has convinced the FDA that advanced macular degeneration in both eyes is uncommon enough to let them seek approval to use the device on people in the US.

Still, the startup’s big ambition and founding purpose is connecting directly to the human brain through a bio-hybrid sensor built from a combination of cultured neurons and silicon. The company is currently designing initial human trials of the device with Yale neurosurgery professor Murat Günel, who told TechCrunch it could offer potential treatments for Parkinson’s disease, among other brain injuries and illnesses.

Get an Early Peek at the Next TechCrunch Disrupt Disrupt, Startup Battlefield, and more will return next year, and you can be at the front of the line. Sign up for our waitlist

Every weekday and Sunday, you can get the best of TechCrunch’s coverage.

TechCrunch Mobility is your destination for transportation news and insight.

Startups are the core of TechCrunch, so get our best coverage delivered weekly.

Original Source Attribution
Published via TechCrunch AI • Source domain: techcrunch.com
Visit Original Source (TechCrunch AI) ↗

Client & Community Discussion (0 Comments)

Share your benchmark feedback, workflow questions, or implementation notes below.

● Live Comments Open
Instant publication • Moderated for technical relevance